Replies to post #353 on Sinobiopharma, Inc. (fka SNBP)

[pappy]

I also like that eps were up in spite a four fold increase in R&D.

However some were disappointed that new products didn't contribute to revenue on a percentage basis.

The flagship product should continue its strong revenue growth with improving margins for a few more years so earnings should show solid gains regardless.

However as long as snbp is seen as a one product company with a large increase in shares outstanding the stock will probably underperform.

New products are not suppose to make a big contribution until next year but I would like to see revenue progress from newer products this year.

As a percentage of total revenue the flagship product is contributing a bigger share of total revenue because of its continued strong growth so when revenue from other products contribute enough to stop this trend I see SNBP deserving a higher p/e ratio since growth from their pipeline of new products can substain good longterm growth of 30%+ for many years after their original producer of revenue see's its growth slowing down.